Bibliography
- Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1
- Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
- Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol 2012;153:468-73
- Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013;120:S3-7
- de Oliveira Dias JR, Rodrigues EB, Maia M, et al. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011;95:1631-7
- Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26
- Joussen AM, Bornfeld N. The treatment of wet age-related macular degeneration. Dtsch Arztebl Int 2009;106:312-17
- Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
- Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-11
- Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
- Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
- Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85
- Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the view studies. Ophthalmology 2014;121:191-201
- Syed BA, Evans JB, Bielory L. Wet AMD market. Nat Rev Drug Discov 2012;11:827
- Regeneron press release, August 6, 2013. Regeneron Reports Second Quarter 2013 Financial and Operating Results
- Beutel J, Rudolf M, Grisanti S. Current and future therapies for age-related macular degeneration. Expert Opin Emerg Drugs 2009;14:341-62
- Englander M, Kaiser PK. Combination therapy for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol 2013;24:233-8
- Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013;120:317-27
- Petrarca R, Dugel PU, Nau J, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. Ophthalmology 2013;120:328-33
- Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology 2013;120:1893-900
- Thrimawithana TR, Young S, Bunt CR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today 2011;16:270-7
- Kuno N, Fujii S. Ocular drug delivery systems for the posterior segment: a review. Retina Today 2012;54-9
- Saati S, Lo R, Li PY, et al. Mini drug pump for ophthalmic use. Trans Am Ophthalmol Soc 2009;107:60-70
- Helzner J. New concepts in anti-VEGF delivery. Ophth Manag 2013; Accessed online Nov 20, 2013
- Clearside Biomedical. Clearside biomedical launched with pipeline and technology focused on drugs delivered to the back of the eye. Available from: http://www.clearsidebio.com/images/newsreleaseclearsideseriesafinancingledbyhatterasfinal.pdf [Accessed on 20 November 2013]
- Tetz M, Rizzo S, Augustin AJ. Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results. Ophthalmologica 2012;227:183-9
- DiPietro C. BCVA improves after intravitreal integrin treatment for wet AMD. OSN Retina 2013;31:30
- Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009;26:204-10
- Available from: clinicaltrials.govNCT01397409
- Available from: clinicaltrials.govNCT01024998
- Bagley RG, Kurtzberg L, Weber W, et al. sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther 2011;10:404-15
- Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica 2012;227(Suppl 1):11-20
- Boehringer backs gene therapy firm Eyevensys. Available from: http://www.pmlive.com/pharma_news/boehringer_backs_gene_therapy_firm_eyevensys_471477 [Accessed on 20 November 2013]
- Available from: clinicaltrials.govNCT01940900
- Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 2009;223:401-10
- Dugel PU. Anti-platelet derived growth factor: where do we stand? Paper presented at: Retina Subspecialty Day; 9 – 10 November 2012; Chicago, IL
- Dugel P. Sirolimus in the treatment of retinal diseases. mTOR inhibitors: a new class of therapeutics. Retina Today 2009;38-41
- Available from: clinicaltrials.govNCT00766337
- Available from: clinicaltrials.govNCT01423149
- Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:16-76
- Available from: clinicaltrials.govNCT00767949
- Kaiser PK, Cruess AF, Bogaert P, et al. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012;250:1563-71